Variable | Sub-HR | 95% CI | P value |
Age (per year) | 1.03 | (1.01 to 1.04) | <0.001 |
Race | |||
White | (ref) | ||
Black | 2.68 | (1.82 to 3.95) | <0.001 |
Hispanic | 2.04 | (1.02 to 4.07) | 0.04 |
Other | 2.54 | (1.27 to 5.09) | 0.009 |
Diabetes mellitus | 1.47 | (1.03 to 2.09) | 0.03 |
Peripheral vascular disease | 2.06 | (1.22 to 3.48) | 0.007 |
Obesity | 1.79 | (1.19 to 2.70) | 0.005 |
Corticosteroid use | 1.90 | (1.14 to 3.17) | 0.01 |
IBD Med category | |||
Mesalazine alone | (ref) | ||
Thiopurine | 1.29 | (0.69 to 2.41) | 0.43 |
Anti-TNF | 1.02 | (0.55 to 1.87) | 0.96 |
Anti-TNF+TP | 1.81 | (0.83 to 3.95) | 0.13 |
Anti-TNF+MTX | 2.31 | (0.83 to 6.48) | 0.11 |
Vedolizumab | 1.98 | (0.85 to 4.65) | 0.12 |
No IBD Meds | 1.64 | (1.12 to 2.42) | 0.01 |
*Death from any non-COVID-19-related cause was treated as a competing event.
IBD, inflammatory bowel disease; MTX, methotrexate; TNF, tumour necrosis factor; TP, thiopurine.